Compare Robinhood Markets, Inc. (HOOD) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Invesco Ltd. — how do they compare? Robinhood Markets, Inc. trades at $109.24 (market cap $96.21B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Robinhood Markets, Inc. is far larger — about 7.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Invesco Ltd. for 77 Days on average.
| HOOD | IVZ | |
|---|---|---|
Market Cap | $96.21B | $13.28B |
Volume | 22,572,153 | 3,698,033 |
Sector | Financials | Financials |
52-Week High | $152.46 | $33.31 |
52-Week Low | $65.16 | $22.44 |
Typical Hold Time | 75 Days | 77 Days |
Enterprise Value | $102.75B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $108.95, down 0.51% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation ratios like P/E of 47.35 are elevated. Recent news highlights expansion into 24/7 stock trading and AI-driven features, signaling growth initiatives.
Outlook remains positive with a consensus price target of $137.53, offering ~26% upside, but risks include high valuation sensitivity and competitive pressures in the brokerage sector. Earnings beat in two of the last three quarters supports growth trajectory, though investors should monitor execution on new product launches and regulatory developments.
Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.
The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
